Laboratory of Biomolecular Research

LBRlogo.jpg The goal of the Laboratory of Biomolecular Research (LBR) is to provide an atomic level understanding on how the structure and dynamics of proteins and their complexes control essential biological processes in the areas of cell division and signaling. Our mission aligns with one of PSI’s main research focuses: The investigation of fundamental molecular mechanisms that determine human health and disease.

More information

Center of Radiopharmaceutical Sciences

zrw1.jpg The Center of Radiopharmaceutical Sciences pursues research in the fields of tracer preparation and in vivo imaging of tissues, in particular of disseminated tumors that cannot be removed surgically or by external radiation therapy. The laboratory is operated jointly by ETH Z├╝rich and PSI. The laboratory creates therapeutic molecules by combining particular types of biomolecules, such as for instance antibodies, with radioactive nuclides. These reagents are used to image tumors and to selectively target and destroy tumor cells in animal models. PSI cooperates with universities, hospitals and the pharmaceutical industry to ensure the most effective coordination of its basic research capabilities with clinical applications.

More information

Laboratory of Nanoscale Biology

The Laboratory of Nanoscale Biology (LNB) investigates the molecular structure and dynamics of complex molecular machines and cascades within the context of the living cell. Technological developments at the PSI provide novel approaches for studying fundamental, molecular processes of life within their physiological context. Electron diffraction and cryo-electron microscopy of bio-molecular complexes form the technological basis of the LNB, together with electron tomography and X-ray diffractive imaging of larger, nanoscopic structures. We develop these technologies in studies of fundamental, molecular aspects of neuro-degeneration and cell motility, and investigate other fundamental processes of life in collaboration. Intellectual property on novel technologies developed at the LNB may lead to commercial spin-outs.

More information